Business Wire

Velodyne Lidar’s Intelligent Infrastructure Solution Selected for Major Deployment in University of California, Irvine Smart Cities Initiative

28.9.2021 13:48:00 EEST | Business Wire | Press release

Share

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced its Intelligent Infrastructure Solution has been selected by the HORIBA Institute for Mobility and Connectivity2 (HIMaC2) in the University of California, Irvine (UCI) Samueli School of Engineering. HIMaC2 plans to equip 25 intersections at UCI and the adjacent City of Irvine with Velodyne’s lidar-based Intelligent Infrastructure Solution as part of a major study on improving traffic and energy efficiency, road safety and air quality.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005328/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Velodyne Lidar announced its Intelligent Infrastructure Solution has been selected by the HORIBA Institute for Mobility and Connectivity² (HIMaC²) in the University of California, Irvine (UCI) Samueli School of Engineering. HIMaC² will use Velodyne’s lidar-based solution as part of a major study on improving traffic and energy efficiency, road safety and air quality. (Photo: Velodyne Lidar)

The Intelligent Infrastructure Solution deployment is supported by a $6 million grant recently awarded to HIMaC2 by the Vehicle Technology Office of the U.S. Department of Energy (DOE). HIMaC2 will create a Public Road Network Platform for the development, evaluation and deployment of emerging and future connected and autonomous vehicle (CAV) technologies. The Intelligent Infrastructure Solution combines Velodyne’s award-winning lidar sensors with powerful AI software to monitor traffic networks and public spaces.

Also included in the project are Bluecity, Argonne National Laboratory (ANL), the UCI Institute of Transportation Studies, Toyota Motor of North America, Pony.ai and Hyundai Mobis. Research shows traffic coordination of intersections and CAVs based on reliable data and analytics can reduce congestion between 20-to-30 percent and emissions between 5-to-15 percent while also improving safety.

“The program looks to advance connected and autonomous transportation and show how they can contribute to smarter, safer infrastructure for our communities,” said UCI Engineering Professor Scott Samuelsen, Principal Investigator in the HIMaC2 program. “By deploying Velodyne’s automated monitoring and control in an intersection network, backbone data can be generated and utilized to demonstrate improved safety, energy efficiency and traffic flow to which cities aspire. With its deployment at 25 intersections, this initiative will be the largest lidar-based traffic monitoring solution in the world.”

HIMaC2 will study how traffic coordination can be improved based on reliable data and analytics generated by the Intelligent Infrastructure Solution. By implementing advanced infrastructure monitoring as a V2X (vehicle to everything) solution, the HIMaC2 program will look to generate critical data needed to improve traffic and crowd flow, path planning, and protect vulnerable road users in all weather and lighting conditions. Distinct advantages of the Intelligent Infrastructure Solution include its ability to leverage as few as one unit per intersection which supports scalability. Additionally, lidar sensors do not identify individuals’ facial characteristics, an important privacy factor for civic applications.

“The HIMaC2 program is tackling one of the most challenging and pervasive infrastructure problems that cities face — how to improve traffic flows and safeguard road users,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “Velodyne believes that smart infrastructure integrated with connected and autonomous vehicles have the potential to deliver game-changing improvements in roadway efficiency and safety. We look forward to working with the HIMaC2 team to explore how to create a more sustainable, safer future for our transportation infrastructure.”

Velodyne’s Intelligent Infrastructure Solution

Velodyne’s Intelligent Infrastructure Solution creates a real-time 3D map of roads and intersections, providing precise traffic monitoring and analytics that is not possible with other types of sensors like cameras or radar. It reliably collects data in any lighting or weather condition, supporting year-round operation, while also protecting people's privacy. The solution advances safety through multimodal analytics that detect various road users including vehicles, pedestrians, and cyclists. It can predict, diagnose, and address road safety challenges, helping municipalities and other customers make informed decisions to take corrective action. For more information on the Intelligent Infrastructure Solution, contact Velodyne Sales: 669.275.2526, sales@velodyne.com.

About the HORIBA Institute for Mobility and Connectivity2 (HIMaC2)

Located at the UCI Samueli School of Engineering “Advanced Power and Energy Program (APEP),” HIMaC2 focuses on the electrochemical powerplants (batteries and fuel cells) powering zero-emission vehicles, the integration of the energy and transportation sectors through electricity and hydrogen under a renewable energy paradigm, and the future of emerging connected and autonomous vehicle. The facilities encompass a Vehicle Evolution Laboratory, a Grid Evolution Laboratory, a Connected and Autonomous Mobility Laboratory, and an Analytic Laboratory.

About Velodyne Lidar

Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne, the global leader in lidar, is known for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.

Forward Looking Statements

This press release contains “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, and competition. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “can,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include uncertainties regarding government regulation and adoption of lidar, the uncertain impact of the COVID-19 pandemic on Velodyne’s and its customers’ businesses; Velodyne’s ability to manage growth; Velodyne’s ability to execute its business plan; uncertainties related to the ability of Velodyne’s customers to commercialize their products and the ultimate market acceptance of these products; the rate and degree of market acceptance of Velodyne’s products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne’s current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne’s intellectual property; and general economic and market conditions impacting demand for Velodyne’s products and services. For more information about risks and uncertainties associated with Velodyne’s business, please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” sections of Velodyne’s SEC filings, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements in this press release are based on information available to Velodyne as of the date hereof, Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Velodyne Investor Relations
InvestorRelations@velodyne.com

Velodyne Media
Codeword
Liv Allen
velodyne@codewordagency.com

HIMaC2 Media
William Gary
949-824-7302, Ext. 11131
wmg@apep.uci.edu

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye